All Updates

All Updates

icon
Filter
Partnerships
Psyence Biomed partners with PsyLabs to supply nature-derived psilocybin for AUD treatment research
Psychedelic Medicine
Sep 4, 2024
This week:
Partnerships
Apple discloses use of AWS GenAI chips at re:Invent 2024 conference
Generative AI Infrastructure
Today
Product updates
AWS launches Automated Reasoning checks to combat AI hallucinations
Generative AI Infrastructure
Today
Product updates
Roonyx releases enhanced BNPL platform to facilitate secure transactions
Buy Now, Pay Later
Yesterday
Product updates
AWS announces next generation of SageMaker platform at re:Invent 2024
Generative AI Infrastructure
Yesterday
Product updates
Equal1 launches quantum controller chip for cryogenic computing
Quantum Computing
Yesterday
Partnerships
Exotec partners with BlueStar to deploy Skypod warehouse automation system
Logistics Tech
Yesterday
Partnerships
Amaero enters long-term supply agreement with Perryman
Additive Manufacturing
Yesterday
Product updates
Raise3D launches six new resins for DF2 DLP solution
Additive Manufacturing
Yesterday
M&A
Anzu Partners acquires voxeljet for EUR 20 million
Additive Manufacturing
Yesterday
Funding
Soda Health raises USD 50 million in oversubscribed Series B funding to scale operations
Health Benefits Platforms
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Sep 4, 2024

Psyence Biomed partners with PsyLabs to supply nature-derived psilocybin for AUD treatment research

Partnerships

  • Psyence Biomed, a division of Psyence that specializes in natural psilocybin products, has entered a worldwide exclusive licensing agreement with PsyLabs, a psychedelic active pharmaceutical ingredient development company, for nature-derived psilocybin supply.

  • Under the agreement, PsyLabs will provide Psyence Biomed with pharmaceutical-grade, EU GMP nature-derived psilocybin for evaluation in clinical trials as a potential treatment for alcohol use disorder (AUD) and other substance use disorders. Psyence Biomed plans to begin with a clinical trial in AUD, while PsyLabs will conduct further development work on the licensed product through 2024 and into 2025.

  • Analyst QuickTake: Psyence previously partnered with Filament Health for the supply of nature-derived psilocybin. However, this partnership was terminated in July 2024 , as the company sought new partners to support its clinical trials for AUD.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.